Development cooperation between Artimplant and Mölnlycke Health Care terminated
Development cooperation between Artimplant and Mölnlycke Health Care terminated The contract between Artimplant and Mölnlycke Health Care concerning development and licensing of products for wound healing has been terminated. "Artimplant's biomaterial Artelon has been tested over several years by Mölnlycke Health Care with the aim of developing products for the treatment of deep wounds. Artimplant's technology is very promising, but in consultation with Artimplant, we have chosen to terminate the project to focus on other prioritized projects," says Anders Husmark, Vice President, Business